Global pharma major Lupin Limited (Lupin) today announced the appointment of Claus Jepsen as President, Global Specialty. He brings over three decades of experience in commercial strategy, portfolio management, and launch planning across Europe, Asia, and the United States. Claus joins Lupin from Takeda Pharmaceuticals, where he led the Global Strategy for Rare Diseases.
Prior to that Claus was at GlaxoSmithKline, where he served in many roles including country head in Asia, and Global franchise management in Immunology, Respiratory and Neurology therapeutic areas. Claus has launched major brands like Ellipta in the U.S. and led Advair and Seretide success in Europe and U.S.
Commenting on the appointment, Lupin’s CEO, Vinita Gupta said, “We are delighted to welcome Claus to our executive leadership team. His experience in leading specialty strategy, commercial planning and portfolio choices across key markets will enable us to build our Specialty brand business.”
